Analeptic effects of N-sulfamoyl-hexahydro-azepine, SaH 41-178.
D000700:Analgesics / Q000494:pharmacology*; D000818:Animals; D001381:Azepines / Q000494:pharmacology*; D002319:Cardiovascular System / Q000187:drug effects; D002415:Cats; D002490:Central Nervous System / Q000187:drug effects; D000697:Central Nervous System Stimulants; D004315:Doxapram / Q000494:pharmacology; D004567:Electrodes, Implanted; D004569:Electroencephalography; D006591:Hexobarbital / Q000494:pharmacology; D008297:Male; D051379:Mice; D010424:Pentobarbital / Q000494:pharmacology; D010433:Pentylenetetrazole / Q000494:pharmacology; D012137:Respiratory System / Q000187:drug effects; D012890:Sleep / Q000187:drug effects; D013449:Sulfonamides / Q000494:pharmacology*
D000700:Analgesics; D001381:Azepines; D000697:Central Nervous System Stimulants; D013449:Sulfonamides; C002494:SaH 41-178; D004315:Doxapram; D006591:Hexobarbital; D010424:Pentobarbital; D010433:Pentylenetetrazole